The Europe Wound Debridement Market should witness market growth of 5.1% CAGR during the forecast period (2022-2028).
The prominent factor that is driving the growth of the market is the increase in diabetes incidences as well as the rise in wounds associated with diabetes. People who have diabetes have an increased risk of developing chronic wounds, necessitating debridement procedures. It is well-known that poor quality of life, life-threatening infections, and amputations are some of diabetic foot ulcers’ dangerous consequences.
In addition, diabetic wounds may heal slowly and become long-lasting, as they can also reoccur even after healing. Therefore, wound debridement procedures become extremely important and even lifesaving in the case of diabetic wounds. Consequently, with the rising diabetic population of the world, incidences of chronic wounds are further expected to increase.
According to recent publications by the International Diabetes Federation (IDF), the diabetic population in the world will grow to around 783 million by 2045 and 643 million in 2030 from the present figures of 537 million in 2021. The same report also stated that approximately 541 million adults in the world are at risk of acquiring type 2 diabetes.
According to the WHO, diabetes prevalence is rising in the region, with approximately 10 to 12 % of the population of the European Union’s Member States suffering from the disease. This increase in prevalence is in tandem with the growing trends of obesity and overweight, physical inactivity, socioeconomic disadvantage, and unhealthy diets. In addition to diabetes, these risk factors propel the development of noncommunicable diseases (NCDs) like chronic respiratory disease, cardiovascular diseases, and cancer.
The Germany market dominated the Europe Wound Debridement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $401.9 million by 2028. The UK market is anticipated to grow at a CAGR of 4.2% during (2022-2028). Additionally, The France market would exhibit a CAGR of 5.9% during (2022-2028).
Based on Mode of Purchase, the market is segmented into Prescription, Over The Counter and Others. Based on Product, the market is segmented into Medical Gauzes, Gels, Surgical Devices, Ultrasonic Devices, Ointments & Creams and Others. Based on Method, the market is segmented into Surgical, Autolytic, Enzymatic, Mechanical and Others. Based on Wound Type, the market is segmented into Diabetic Foot Ulcers, Pressure Ulcers, Burn Wounds and Venous Leg Ulcers & Others. Based on End-use, the market is segmented into Hospitals, Homecare and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
The prominent factor that is driving the growth of the market is the increase in diabetes incidences as well as the rise in wounds associated with diabetes. People who have diabetes have an increased risk of developing chronic wounds, necessitating debridement procedures. It is well-known that poor quality of life, life-threatening infections, and amputations are some of diabetic foot ulcers’ dangerous consequences.
In addition, diabetic wounds may heal slowly and become long-lasting, as they can also reoccur even after healing. Therefore, wound debridement procedures become extremely important and even lifesaving in the case of diabetic wounds. Consequently, with the rising diabetic population of the world, incidences of chronic wounds are further expected to increase.
According to recent publications by the International Diabetes Federation (IDF), the diabetic population in the world will grow to around 783 million by 2045 and 643 million in 2030 from the present figures of 537 million in 2021. The same report also stated that approximately 541 million adults in the world are at risk of acquiring type 2 diabetes.
According to the WHO, diabetes prevalence is rising in the region, with approximately 10 to 12 % of the population of the European Union’s Member States suffering from the disease. This increase in prevalence is in tandem with the growing trends of obesity and overweight, physical inactivity, socioeconomic disadvantage, and unhealthy diets. In addition to diabetes, these risk factors propel the development of noncommunicable diseases (NCDs) like chronic respiratory disease, cardiovascular diseases, and cancer.
The Germany market dominated the Europe Wound Debridement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $401.9 million by 2028. The UK market is anticipated to grow at a CAGR of 4.2% during (2022-2028). Additionally, The France market would exhibit a CAGR of 5.9% during (2022-2028).
Based on Mode of Purchase, the market is segmented into Prescription, Over The Counter and Others. Based on Product, the market is segmented into Medical Gauzes, Gels, Surgical Devices, Ultrasonic Devices, Ointments & Creams and Others. Based on Method, the market is segmented into Surgical, Autolytic, Enzymatic, Mechanical and Others. Based on Wound Type, the market is segmented into Diabetic Foot Ulcers, Pressure Ulcers, Burn Wounds and Venous Leg Ulcers & Others. Based on End-use, the market is segmented into Hospitals, Homecare and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
Scope of the Study
By Mode of Purchase
- Prescription
- Over The Counter
- Others
By Product
- Medical Gauzes
- Gels
- Surgical Devices
- Ultrasonic Devices
- Ointments & Creams
- Others
By Method
- Surgical
- Autolytic
- Enzymatic
- Mechanical
- Others
By Wound Type
- Diabetic Foot Ulcers
- Pressure Ulcers
- Burn Wounds
- Venous Leg Ulcers & Others
By End-use
- Hospitals
- Homecare
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- 3M Company
- Coloplast Group
- Medline Industries, Inc.
- Smith & Nephew PLC
- Medtronic PLC
- ConvaTec Group PLC
- Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
- Johnson & Johnson (Ethicon, Inc.)
- Baxter International, Inc.
- Molnlycke Health Care AB
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Wound Debridement Market, by Mode of Purchase
1.4.2 Europe Wound Debridement Market, by Product
1.4.3 Europe Wound Debridement Market, by Method
1.4.4 Europe Wound Debridement Market, by Wound Type
1.4.5 Europe Wound Debridement Market, by End-use
1.4.6 Europe Wound Debridement Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Europe Wound Debridement Market by Mode of Purchase
4.1 Europe Prescription Market by Country
4.2 Europe Over The Counter Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Wound Debridement Market by Product
5.1 Europe Medical Gauzes Market by Country
5.2 Europe Gels Market by Country
5.3 Europe Surgical Devices Market by Country
5.4 Europe Ultrasonic Devices Market by Country
5.5 Europe Ointments & Creams Market by Country
5.6 Europe Others Market by Country
Chapter 6. Europe Wound Debridement Market by Method
6.1 Europe Surgical Market by Country
6.2 Europe Autolytic Market by Country
6.3 Europe Enzymatic Market by Country
6.4 Europe Mechanical Market by Country
6.5 Europe Others Market by Country
Chapter 7. Europe Wound Debridement Market by Wound Type
7.1 Europe Diabetic Foot Ulcers Market by Country
7.2 Europe Pressure Ulcers Market by Country
7.3 Europe Burn Wounds Market by Country
7.4 Europe Venous Leg Ulcers & Others Market by Country
Chapter 8. Europe Wound Debridement Market by End-use
8.1 Europe Hospitals Market by Country
8.2 Europe Homecare Market by Country
8.3 Europe Others Market by Country
Chapter 9. Europe Wound Debridement Market by Country
9.1 Germany Wound Debridement Market
9.1.1 Germany Wound Debridement Market by Mode of Purchase
9.1.2 Germany Wound Debridement Market by Product
9.1.3 Germany Wound Debridement Market by Method
9.1.4 Germany Wound Debridement Market by Wound Type
9.1.5 Germany Wound Debridement Market by End-use
9.2 UK Wound Debridement Market
9.2.1 UK Wound Debridement Market by Mode of Purchase
9.2.2 UK Wound Debridement Market by Product
9.2.3 UK Wound Debridement Market by Method
9.2.4 UK Wound Debridement Market by Wound Type
9.2.5 UK Wound Debridement Market by End-use
9.3 France Wound Debridement Market
9.3.1 France Wound Debridement Market by Mode of Purchase
9.3.2 France Wound Debridement Market by Product
9.3.3 France Wound Debridement Market by Method
9.3.4 France Wound Debridement Market by Wound Type
9.3.5 France Wound Debridement Market by End-use
9.4 Russia Wound Debridement Market
9.4.1 Russia Wound Debridement Market by Mode of Purchase
9.4.2 Russia Wound Debridement Market by Product
9.4.3 Russia Wound Debridement Market by Method
9.4.4 Russia Wound Debridement Market by Wound Type
9.4.5 Russia Wound Debridement Market by End-use
9.5 Spain Wound Debridement Market
9.5.1 Spain Wound Debridement Market by Mode of Purchase
9.5.2 Spain Wound Debridement Market by Product
9.5.3 Spain Wound Debridement Market by Method
9.5.4 Spain Wound Debridement Market by Wound Type
9.5.5 Spain Wound Debridement Market by End-use
9.6 Italy Wound Debridement Market
9.6.1 Italy Wound Debridement Market by Mode of Purchase
9.6.2 Italy Wound Debridement Market by Product
9.6.3 Italy Wound Debridement Market by Method
9.6.4 Italy Wound Debridement Market by Wound Type
9.6.5 Italy Wound Debridement Market by End-use
9.7 Rest of Europe Wound Debridement Market
9.7.1 Rest of Europe Wound Debridement Market by Mode of Purchase
9.7.2 Rest of Europe Wound Debridement Market by Product
9.7.3 Rest of Europe Wound Debridement Market by Method
9.7.4 Rest of Europe Wound Debridement Market by Wound Type
9.7.5 Rest of Europe Wound Debridement Market by End-use
Chapter 10. Company Profiles
10.1 Medtronic PLC
10.1.1 Company overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.1.6 SWOT Analysis
10.2 ConvaTec Group PLC
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Product Category and Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.2.5.2 Acquisitions and Mergers:
10.2.5.3 Product Launches and Expansions:
10.3 Coloplast Group
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental and Regional Analysis
10.3.4 Research & Development Expense
10.4 3M Company
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Acquisitions and Mergers:
10.5 Smith & Nephew PLC
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Geographical Expansions:
10.5.5.2 Acquisitions and Mergers:
10.6 Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.7 Baxter International, Inc.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental Analysis
10.7.4 Research & Development Expense
10.7.5 Recent strategies and developments:
10.7.5.1 Acquisition and Mergers:
10.8 Johnson & Johnson (Ethicon, Inc.)
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental &Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Acquisition and Mergers:
10.9 Medline Industries, Inc.
10.9.1 Company Overview
10.9.2 Recent strategies and developments:
10.9.2.1 Partnerships, Collaborations, and Agreements:
10.10. Molnlycke Health Care AB
10.10.1 Company Overview
10.10.2 Recent strategies and developments:
10.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- 3M Company
- Coloplast Group
- Medline Industries, Inc.
- Smith & Nephew PLC
- Medtronic PLC
- ConvaTec Group PLC
- Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
- Johnson & Johnson (Ethicon, Inc.)
- Baxter International, Inc.
- Molnlycke Health Care AB
Methodology
LOADING...
